Allogenic Cell Therapies Market Expected to Witness High Growth in Asia Pacific Region Due to Rising Pharma Investments and Expanding Infrastructure

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Allogenic Cell Therapies Market- by Cell Type(Cardiosphere-Derived Cells (CDCs), Fibroblasts, T-cells, Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs) and Others),Tissue Source(Skin, Blood, PBC, BM and Others), Indication (Acute graft-versus-host disease (GVHD), Chronic Ulcers and Diabetic Foot Ulcers, Osteoarthritis, Crohn's Disease, Cardiovascular Disease, Solid Tumors/Cancers and Others (Alzheimer's Disease, etc.)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the globalAllogenic Cell Therapiesmarketwill be valued at 997.36 Million in 2022. It is expected to reach 2853.34 Million by the year 2031, with a CAGR of 12.7% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1084

Allogeneic cell therapy products are exhibiting encouraging outcomes across both preclinical and clinical stages. These therapies utilize healthy cells derived from unrelated donors and are designed to treat multiple patients from a single cell source. The treatment involves the transplantation of donor-derived stem cells to replace damaged or destroyed cells in the recipient. The increasing demand for advanced therapeutic approaches targeting immunological disorders, neurodegenerative conditions, and myocardial infarctions has contributed to the growth of allogeneic cell therapy adoption, alongside a surge in stem cell therapy initiatives, research activity, and funding for cell-based studies.

The allogeneic cell therapy manufacturing market is projected to witness robust growth over the forecast period, driven by multiple factors. These include the escalating prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders; growing government support and funding for stem cell therapies; an ageing global population; continual improvements in healthcare infrastructure; and technological advancements. Additionally, heightened public awareness of the clinical benefits associated with allogeneic cell therapies is further stimulating market demand. Numerous pharmaceutical companies are actively launching allogeneic therapies to address the needs of patients suffering from chronic illnesses.

To meet the growing demand for cost-effective and scalable cell and gene therapies, contract research organizations (CROs) are expanding their bioassay service offerings, thereby creating new avenues for market growth. However, the high costs associated with therapy development and concerns regarding immunological rejection may act as constraints on the market's expansion in the coming years.

Regionally, North America is expected to maintain a dominant position in the allogeneic cell therapy market, supported by the high prevalence of chronic diseases, significant investments in research and development, and the rapid integration of advanced technologies. Meanwhile, the Asia-Pacific region is poised for substantial growth, fueled by the expansion of pharmaceutical manufacturing capabilities and rising investment in cell therapy research and infrastructure.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

Major market players operating in the Allogenic Cell Therapies market include
AtaraBiotherapeutics, ArtivaBiotherapeutic, Adaptimmune Therapeutics plc, Adicet Bio, Inc., Allogene Therapeutics, Athersys, Inc., BioCardia Inc., Bluebird Bio, BlueRock Therapeutics LP, Bone Therapeutics, Celyad, Capricor Therapeutics, Cellectis, Cyto Therapeutics Pty Limited, Cynata Therapeutics, Century Therapeutics, GammaDelta Therapeutics Limited, Fate Therapeutics, Osiris Therapeutics, Inc., Organogenesis Inc., Mesoblast Ltd, MEDIPOST, Nkarta, Inc., NantKwest, Pluristem Therapeutics Inc, Regeneus, Lineage Cell Therapeutics, Inc., Stempeutics, Stemedica Cell Technologies, Inc., TiGenix (Takeda) and TCR2 Therapeutics.

Recent collaborations and agreements in the market:
• In January 2022,Rexlemestrocel-L (MPC-06-ID), an allogeneic cell therapy, was tested in a Phase 3 trial on patients with CLBP (chronic low back pain) associated with DDD. Mesoblast Limited (Australi), a global leader in allogeneic cellular medicines for inflammatory diseases, presented the 36-month follow-up results (degenerative disc disease). In this study, a single intra-discal injection of the rexlemestrocel-L+hyaluronic acid (HA) carrier resulted in a significant three-year reduction in back pain.
• In November 2021, a non-binding term sheet for the global rights to ALLOB, the allogeneic bone cell therapy of BONE THERAPEUTICS (Belgium), was signed between Link Health Pharma Co., Ltd. and the cell therapy firm.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1084

Market Segments
Global Allogenic Cell Therapies Market, by Cell Type, 2022-2030 (Value US$ Mn)
• Cardiosphere-Derived Cells (CDCs)
• Fibroblasts
• T-cells
• Mesenchymal Stem Cells (MSCs)
• Hematopoietic Stem Cells (HSCs)
• Others
Global Allogenic Cell Therapies Market, by Tissue Source, 2022-2030 (Value US$ Mn)
• Skin
• Blood
• PBC
• BM
• Others
Global Allogenic Cell Therapies Market, by Indication, 2022-2030 (Value US$ Mn)
• Acute graft-versus-host disease (GVHD)
• Chronic Ulcers and Diabetic Foot Ulcers
• Osteoarthritis
• Crohn's Disease
• Cardiovascular Disease
• Solid Tumors/Cancers
• Others (Alzheimer's Disease, etc.)
Global Allogenic Cell Therapies Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Allogenic Cell Therapies Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Allogenic Cell Therapies Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Allogenic Cell Therapies Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Allogenic Cell Therapies Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Allogenic Cell Therapies Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/global-allogenic-cell-therapies-market/1084

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Allogenic Cell Therapies market
 To receive an industry overview and future trends of theAllogenic Cell Therapies market
 To analyzethe Allogenic Cell Therapies market drivers and challenges
 To get information on the Allogenic Cell Therapies marketvalue (US$ Mn) forecast to 2030
 Significantinvestments, mergers &acquisitions in the Allogenic Cell Therapies marketindustry

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.